<unk>  was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression.<unk> , or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).
Olanzapine/fluoxetine
Aripiprazole/sertraline
Naltrexone/bupropion
Amitriptyline/chlordiazepoxide
Brief psychotherapy
Serdexmethylphenidate/dexmethylphenidate
Aripiprazole lauroxil
Insight-oriented psychotherapy